Regulatory Filings • Jan 7, 2022
Regulatory Filings
Open in ViewerOpens in native device viewer
Under the liquidity contract entered into between ONXEO and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2021:
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the soughtafter field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.
platON™ is Onxeo's proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company's product pipeline.
AsiDNA™, the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNAdamaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is evaluating the safety and efficacy of AsiDNA™ at a dose of 600 mg in combination with the reference chemotherapy, carboplatin -/+ paclitaxel, in advanced metastatic tumors. Preliminary results from both cohorts showed good tolerability, stabilization of the disease and an increase in treatment duration compared to previous treatments. The ongoing REVOCAN phase 1b/2 study evaluates the effect of AsiDNA™ on the acquired resistance to PARP inhibitor niraparib in relapsed ovarian cancer (sponsored by Gustave Roussy). A phase 1b/2 study, AsiDNA™ Children, will be initiated in 2021 to evaluate the association of AsiDNA™ with radiotherapy in children with relapsed high-grade glioma (sponsored by Institut Curie).
OX401 is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.
This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent Company's registration document or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Company Group (www.onxeo.com) and/or the AMF (www.amf-france.org).
Brigitte Le Guennecy, Relations Investisseurs [email protected] +33 1 45 58 76 00
Relations Presse Nicolas Merigeau NewCap [email protected] +33 1 44 71 94 98
Relations Investisseurs / Communication stratégique Dušan Orešanský / Emmanuel Huynh NewCap
+33 1 44 71 94 92
LifeSci Advisors [email protected] +1 212 915 2578
First North Kapital Partner www.kapitalpartner.dk [email protected] +45 89 88 78 46
| Buy Side | Sell Side | |||||
|---|---|---|---|---|---|---|
| Number of executions |
Number of shares |
Traded volume in EUR |
Number of executions |
Number of shares |
Traded volume in EUR |
|
| Total | 256 | 357,510 | 179,383.26 | 155 | 221,580 | 115,071.34 |
| 01/07/2021 | 1 | 1 | 0.64 | 1 | 1 | 0.64 |
| 07/07/2021 | - | - | - | 2 | 11 | 7.15 |
| 08/07/2021 | 7 | 7,733 | 4,717.13 | 1 | 1 | 0.63 |
| 09/07/2021 | 2 | 2,000 | 1,220.00 | 14 | 10,767 | 6,783.21 |
| 15/07/2021 | 2 | 5,001 | 3,100.62 | 1 | 1 | 0.63 |
| 16/07/2021 | 4 | 2,810 | 1,714.10 | - | - | - |
| 19/07/2021 | 7 | 6,457 | 3,938.77 | - | - | - |
| 20/07/2021 | 4 | 1,500 | 915.00 | - | - | - |
| 21/07/2021 | 2 | 1,000 | 600.00 | - | - | - |
| 22/07/2021 | - | - | - | 1 | 1 | 0.62 |
| 23/07/2021 | 1 | 1,306 | 783.60 | 4 | 5,000 | 3,050.00 |
| 27/07/2021 | 1 | 1 | 0.61 | 1 | 1 | 0.61 |
| 28/07/2021 | 10 | 9,694 | 5,816.40 | - | - | - |
| 29/07/2021 | 1 | 1 | 0.59 | 1 | 1 | 0.59 |
| 03/08/2021 | 1 | 1,000 | 580.00 | - | - | - |
| 06/08/2021 | 2 | 2,001 | 1,160.58 | - | - | - |
| 09/08/2021 | 5 | 1,701 | 986.58 | - | - | - |
| 10/08/2021 | 3 | 83 | 48.14 | 1 | 1 | 0.58 |
| 11/08/2021 | 1 | 216 | 125.28 | - | - | - |
| 16/08/2021 | 6 | 5,000 | 2,850.00 | - | - | - |
| 17/08/2021 | - | - | - | 4 | 10,000 | 5,900.00 |
| 18/08/2021 | 4 | 10,000 | 5,700.00 | - | - | - |
| 19/08/2021 | - | - | - | 3 | 5,000 | 2,900.00 |
| 20/08/2021 | 2 | 1,938 | 1,104.66 | - | - | - |
| 23/08/2021 | 1 | 1 | 0.59 | 2 | 2 | 1.18 |
| 24/08/2021 | 2 | 5,415 | 3,086.55 | 4 | 9,999 | 5,799.42 |
| 25/08/2021 | 1 | 1 | 0.58 | 2 | 5,151 | 3,090.60 |
| 26/08/2021 | - | - | - | 1 | 4,849 | 2,957.89 |
| 27/08/2021 | 7 | 6,046 | 3,567.14 | 1 | 1 | 0.60 |
| 30/08/2021 | 1 | 1,601 | 944.59 | - | - | - |
| 01/09/2021 | 2 | 5,000 | 2,900.00 | - | - | - |
| 03/09/2021 | - | - | - | 2 | 7,390 | 4,434.00 |
| 07/09/2021 | 1 | 5,000 | 2,900.00 | 7 | 3,137 | 1,850.83 |
| 08/09/2021 | - | - | - | 4 | 1,863 | 1,099.17 |
| 09/09/2021 | - | - | - | 2 | 523 | 313.80 |
| 10/09/2021 | 5 | 5,000 | 2,950.00 | 1 | 2,087 | 1,252.20 |
| 14/09/2021 | 5 | 5,000 | 2,900.00 | - | - | - |
| 17/09/2021 | 2 | 5,000 | 2,850.00 | 1 | 790 | 458.20 |
| 20/09/2021 | 2 | 5,000 | 2,800.00 | 3 | 136 | 77.52 |
| 22/09/2021 | 3 | 10,000 | 5,500.00 | - | - | - |
| 30/09/2021 | 1 | 1 | 0.56 | 1 | 1 | 0.56 |
|---|---|---|---|---|---|---|
| 01/10/2021 | 6 | 4,613 | 2,491.02 | - | - | - |
| 04/10/2021 | 4 | 2,387 | 1,288.98 | 2 | 4,864 | 2,675.20 |
| 05/10/2021 | 6 | 8,000 | 4,240.00 | 5 | 2,746 | 1,482.84 |
| 06/10/2021 | 3 | 4,945 | 2,571.40 | - | - | - |
| 07/10/2021 | 2 | 5,055 | 2,578.05 | 1 | 1 | 0.52 |
| 08/10/2021 | - | - | - | 3 | 901 | 468.52 |
| 12/10/2021 | 4 | 10,000 | 4,900.00 | 2 | 3,196 | 1,629.96 |
| 13/10/2021 | 3 | 5,000 | 2,450.00 | 10 | 14,536 | 7,558.72 |
| 14/10/2021 | 3 | 4,247 | 2,165.97 | 1 | 1,391 | 737.23 |
| 15/10/2021 | 4 | 5,753 | 2,991.56 | - | - | - |
| 21/10/2021 | 3 | 2,894 | 1,447.00 | - | - | - |
| 22/10/2021 | 3 | 2,106 | 1,053.00 | - | - | - |
| 26/10/2021 | 6 | 5,000 | 2,500.00 | - | - | - |
| 27/10/2021 | - | - | - | 1 | 33 | 16.83 |
| 28/10/2021 | 2 | 5,000 | 2,500.00 | 2 | 477 | 243.27 |
| 29/10/2021 | 1 | 1 | 0.50 | 1 | 1 | 0.50 |
| 03/11/2021 | 4 | 5,000 | 2,500.00 | 1 | 1,719 | 876.69 |
| 04/11/2021 | 2 | 2,918 | 1,429.82 | - | - | - |
| 05/11/2021 | 2 | 2,082 | 1,020.18 | - | - | - |
| 11/11/2021 | 3 | 5,000 | 2,400.00 | - | - | - |
| 12/11/2021 | 3 | 10,000 | 4,700.00 | 1 | 5,000 | 2,400.00 |
| 16/11/2021 | 13 | 18,732 | 8,429.40 | - | - | - |
| 17/11/2021 | 4 | 6,268 | 2,632.56 | - | - | - |
| 23/11/2021 | 1 | 1 | 0.43 | 1 | 1 | 0.43 |
| 24/11/2021 | 3 | 7,055 | 2,892.55 | - | - | - |
| 26/11/2021 | 3 | 5,000 | 2,050.00 | 2 | 1,778 | 764.54 |
| 29/11/2021 | 1 | 2,945 | 1,178.00 | 7 | 3,222 | 1,385.46 |
| 30/11/2021 | 1 | 2,412 | 964.80 | - | - | - |
| 01/12/2021 | - | - | - | 5 | 5,000 | 2,100.00 |
| 08/12/2021 | 7 | 8,611 | 3,444.40 | - | - | - |
| 09/12/2021 | 6 | 3,000 | 1,260.00 | 8 | 20,000 | 8,800.00 |
| 10/12/2021 | 1 | 977 | 459.19 | 26 | 60,000 | 30,600.00 |
| 14/12/2021 | 7 | 20,000 | 9,800.00 | - | - | - |
| 15/12/2021 | 5 | 3,963 | 1,862.61 | - | - | - |
| 16/12/2021 | 11 | 16,037 | 7,377.02 | - | - | - |
| 20/12/2021 | 4 | 5,000 | 2,350.00 | 2 | 5,000 | 2,400.00 |
| 21/12/2021 | 8 | 25,000 | 11,000.00 | - | - | - |
| 22/12/2021 | 3 | 5,000 | 2,100.00 | 3 | 10,001 | 4,400.44 |
| 23/12/2021 | 7 | 9,211 | 3,960.73 | 2 | 9,465 | 4,164.60 |
| 24/12/2021 | 2 | 5,789 | 2,431.38 | 1 | 534 | 234.96 |
| 28/12/2021 | 2 | 5,000 | 2,100.00 | 1 | 3,686 | 1,584.98 |
| 29/12/2021 | - | - | - | 2 | 1,314 | 565.02 |
| 31/12/2021 | 4 | 5,000 | 2,100.00 | - | - | - |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.